ArticleClinical rheumatology2026
Comparative Value of Traditional versus Novel Immune-Inflammatory Indices in Assessing Disease Activity of Sjögren's Disease: A Multicenter Cohort Study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTo evaluate the comparative value of traditional clinical features and novel immune-inflammatory indices in assessing disease activity in primary Sjögren's Disease (SjD), and to construct a robust classification model for moderate-to-severe disease activity using a machine learning approach.
methodsThis cross-sectional study included 18,738 SjD patients from the Chinese Rheumatism Data Center (CRDC) multicenter prospective cohort. Spearman rank correlation and local polynomial regression (LOESS) were used to explore the relationship between systemic inflammatory indices and the EULAR Sjögren's syndrome disease activity index (ESSDAI). To identify moderate-to-severe disease activity (ESSDAI ≥ 5), data were randomly split into training and validation sets (7:3). Classification models were developed using various machine learning techniques.
resultsHigher ESSDAI scores were significantly associated with elevated levels of both traditional markers (ESR, CRP, IgG) and novel composite indices (NLR, CAR, CLR, IBI) (all p < 0.001). However, these indices exhibited only weak-to-moderate linear correlations with ESSDAI and displayed non-linear saturation trends. In multivariable logistic regression, traditional markers remained independent risk factors, whereas all novel composite indices lost statistical significance, yielding a poor validation area under the curve (AUC) of 0.678. Conversely, the XGBoost model demonstrated modestly favorable overall performance Feature importance analysis revealed that patient-reported outcomes, hemoglobin, WBC, age, and IgG were the top contributors to the model, while novel inflammatory indices were completely excluded.
conclusionNovel immune-inflammatory indices lack provide no independent discriminative value for moderate-to-severe SjD activity when adjusted for traditional parameters. The XGBoost machine learning model effectively handles non-linear variables and highlights the core diagnostic importance of patient-reported outcomes (ESSPRI) and traditional clinical features, providing a favorable evaluation tool. Key Points • Correlation analysis showed that traditional markers (ESR, CRP, IgG) and novel indices (NLR, CAR, CLR, IBI) were significantly associated with higher ESSDAI scores but showed weak-to-moderate linear correlations with nonlinear saturation trends. • In multivariable logistic regression, traditional markers remained independent risk factors, whereas novel indices lost significance. • The XGBoost model outperformed logistic regression and random forest, achieving a validation AUC of 0.701. • Feature importance identified patient-reported outcomes, HB, WBC, age, and IgG as top contributors, while novel indices were excluded.
Indexed as
Identifiers
42446619What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.